London Calling 2024 - Speakers
Speakers
Check out the line up of speaking at London Calling 2024.
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
Oxford Nanopore Technologies
Prof. Matt Brown
)
- Job title
- Institution
- Genomics England, UK
- Biography
Matt Brown is a clinician-scientist who trained initially in medicine and rheumatology in Sydney, Australia before completing a Doctorate of Medicine based at the University of Oxford, focusing on genetics of ankylosing spondylitis. He was appointed Professor of Musculoskeletal Sciences at the University of Oxford in 2004. In 2005, Matt returned to Australia, firstly to The University of Queensland, and in 2016 became Professor and Director of Genomics at Queensland University of Technology. In 2013, he was elected to Fellowship of the Australian Academy of Sciences in recognition for his achievements in genetics research. Matt moved to King’s College London and Guy’s and St Thomas’ Hospitals NHS Trust in 2019 to direct their NIHR Biomedical Research Centre, and in 2021 moved to the position of Chief Scientific Officer of Genomics England. He continues to work in genetics of human diseases, with a particular focus on common and rare bone and joint diseases, and in cancer genomics and personalized medicine. Matt continues to practice rheumatology, with a particular focus on spondyloarthritis.
- Recent publications
Li, Z. et al. Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis. Ann Rheum Dis. 80(9):1168–1174 (2021). DOI:10.1136/annrheumdis-2020-219446
Hanson, A.L. et al. Altered repertoire diversity and disease-associated clonal expansions revealed by T cell receptor immunosequencing in ankylosing spondylitis patients. Arthritis Rheumatol. 72(8):1289–1302 (2020). DOI: 10.1002/art.41252
Yin J., et al. Shotgun metagenomics reveals an enrichment of potentially cross-reactive bacterial epitopes in ankylosing spondylitis patients, as well as the effects of TNFi therapy upon microbiome composition. Ann Rheum Dis. 79(1):132–140 (2020). DOI: 10.1136/annrheumdis-2019-215763